TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03410680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FUERTES
Description: The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
Study: NCT01389791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: priming
Description: Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate and priming
Description: Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
Study: NCT01064778

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low GI
Description: Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI
Description: Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p\<0.001). The test meals will provide 25% of individual daily energy requirements.
Study: NCT04095897

Intervention type: PROCEDURE
Intervention: Pecs II Block
Description: Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
Study: NCT00380809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational Atherectomy + PES

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment (PES without Rotational Atherectomy)
Study: NCT02492126

Intervention type: OTHER
Intervention: Citric Acid
Description: Subjects will undergo cough reflex sensitivity testing to citric acid.
Study: NCT05111340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative score
Description: Creation and validation of a perioperative walk score. The patient has to answer different items.
Study: NCT04484324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercises
Description: Post-facilitation stretch is a technique involves a maximal contraction of the muscle at mid-range with a rapid movement to maximal length followed by a static stretch.
Study: NCT04566796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: give 2 mg/ kg as muscle reversal drug in premature infants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
Study: NCT02281552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
Study: NCT03488212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program
Description: Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
Study: NCT02288312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study: NCT02862015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncothermia
Description: Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX or Gemcitabine based chemotherapy
Description: As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
Study: NCT03488212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program
Description: Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training to Motivate and Support Patients' Weight Loss
Description: Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Behavioral Weight Loss Intervention
Description: For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
Study: NCT01798537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin Colistin Nystatin Vancomycin
Description: All participating study arm patients will receive SDD from admission to discharge
Study: NCT01858909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Administration via oral or via a nasogastric tube followed by 20mL saline
Study: NCT03488212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Intervention
Description: For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss Intervention
Description: For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention for Weight Loss Maintenance and Weight Gain Prevention
Description: After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention
Description: After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention
Description: After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
Study: NCT02862015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX or Gemcitabine based chemotherapy
Description: As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
Study: NCT03080558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Use of Indocyanine Green during Rectal shaving by laparoscopy.
Study: NCT02165319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Barrel
Description: Barrel-shaped endotracheal tube will be used during general anesthesia.
Study: NCT02165319

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tapered
Description: Tapered-shaped tube will be used during general anesthesia.
Study: NCT01193491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-493
Description: Capsules, ascending dose, multiple schedules
Study: NCT03332225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with Placebo
Study: NCT01559584

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ultraviolet A (UVA)
Description: 0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: One monthly injections of intralesional triamcinolone acetonide
Study: NCT04629105

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Longeveron Mesenchymal Stem Cells (LMSCs)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Longeveron Mesenchymal Stem Cells (LMSCs)
Description: Longeveron Mesenchymal Stem Cells (LMSCs)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00239694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: One time preventative vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: One time preventative vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Vaccine
Description: One time preventative vaccine
Study: NCT02184234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antistax film coated tablets
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
Study: NCT04023266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous N-Acetylcysteine
Description: Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
Study: NCT01844063

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Conventional plus BM-MSC treatment
Description: Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Conventional plus UC-MSC treatment
Description: Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma.
Study: NCT04126993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab,
Description: Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study: NCT04126993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study: NCT00611598

Intervention type: OTHER
Intervention: Blood draw and Questionnaires
Description: Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.

Intervention type: OTHER
Intervention: Blood draw and Questionnaires
Description: Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 12,
Description: Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 12,
Description: Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 18
Description: Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT03042572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Mesenchymal Stromal Cell
Description: Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5\*10\^6 MSC per site; total 150\*10\^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
Study: NCT04246359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar
Description: To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon α-2b
Description: To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.
Study: NCT02778477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 24
Description: Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox intramuscularly at Week 24
Description: Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT02778477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06423264
Description: Multiple ascending dose of PF-06423264

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo
Study: NCT02778477

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dose of placebo